Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $352.1 million.

  • Kiniksa Pharmaceuticals International's Cash & Equivalents rose 5734.29% to $352.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $352.1 million, marking a year-over-year increase of 5734.29%. This contributed to the annual value of $183.6 million for FY2024, which is 7005.48% up from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Cash & Equivalents is $352.1 million, which was up 5734.29% from $307.8 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Cash & Equivalents registered a high of $352.1 million during Q3 2025, and its lowest value of $108.0 million during Q4 2023.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Cash & Equivalents had a median value of $200.7 million in 2022 and averaged $203.6 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Cash & Equivalents crashed by 4486.24% in 2022 and then soared by 7005.48% in 2024.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Cash & Equivalents stood at $122.5 million in 2021, then rose by 0.2% to $122.7 million in 2022, then dropped by 12.03% to $108.0 million in 2023, then skyrocketed by 70.05% to $183.6 million in 2024, then surged by 91.8% to $352.1 million in 2025.
  • Its Cash & Equivalents was $352.1 million in Q3 2025, compared to $307.8 million in Q2 2025 and $268.3 million in Q1 2025.